Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 24/04/2019)

PEARLS (MSD)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.

KEYNOTE-671 (MSD)
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA NSCLC.

New trial in start-up: currently no new trials